Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1398513rdf:typepubmed:Citationlld:pubmed
pubmed-article:1398513lifeskim:mentionsumls-concept:C0023434lld:lifeskim
pubmed-article:1398513lifeskim:mentionsumls-concept:C0680730lld:lifeskim
pubmed-article:1398513lifeskim:mentionsumls-concept:C1282907lld:lifeskim
pubmed-article:1398513lifeskim:mentionsumls-concept:C1550594lld:lifeskim
pubmed-article:1398513lifeskim:mentionsumls-concept:C0205396lld:lifeskim
pubmed-article:1398513lifeskim:mentionsumls-concept:C0806140lld:lifeskim
pubmed-article:1398513lifeskim:mentionsumls-concept:C1148554lld:lifeskim
pubmed-article:1398513lifeskim:mentionsumls-concept:C1548760lld:lifeskim
pubmed-article:1398513lifeskim:mentionsumls-concept:C1547300lld:lifeskim
pubmed-article:1398513lifeskim:mentionsumls-concept:C0580822lld:lifeskim
pubmed-article:1398513pubmed:issue3-4lld:pubmed
pubmed-article:1398513pubmed:dateCreated1992-11-10lld:pubmed
pubmed-article:1398513pubmed:abstractTextForty-five patients with low grade non-Hodgkin's lymphomas were studied with respect to the fraction of S-phase cells in fresh tumour material by flow cytometric analysis. Patients with stage I lymphomas were treated with radiotherapy, patients with stage II-IV lymphomas with Prednimustine (Sterecyt). Patients with lymphocytic lymphomas of CLL type were only treated if they had symptoms. Median S-phase fraction in the samples was 2.0 per cent. A significantly shorter survival was found for patients with lymphocytic lymphomas with S-phase fractions > 2.0 per cent compared with cases showing lower S-phase fractions. No significant difference in survival was found in the subgroups of immunocytic or follicular and follicular/diffuse centroblastic/centrocytic lymphomas. In a Cox multivariate analysis, in which also age, constitutional symptoms, stage and morphology were included, the fraction of S-phase cells was found to be a statistically significant, prognostic parameter for low grade lymphomas, mainly due to the result in the subgroup of lymphocytic lymphomas.lld:pubmed
pubmed-article:1398513pubmed:languageenglld:pubmed
pubmed-article:1398513pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1398513pubmed:citationSubsetIMlld:pubmed
pubmed-article:1398513pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1398513pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1398513pubmed:statusMEDLINElld:pubmed
pubmed-article:1398513pubmed:issn0278-0232lld:pubmed
pubmed-article:1398513pubmed:authorpubmed-author:LindhJJlld:pubmed
pubmed-article:1398513pubmed:authorpubmed-author:RoosGGlld:pubmed
pubmed-article:1398513pubmed:authorpubmed-author:LennerPPlld:pubmed
pubmed-article:1398513pubmed:authorpubmed-author:JonssonHHlld:pubmed
pubmed-article:1398513pubmed:issnTypePrintlld:pubmed
pubmed-article:1398513pubmed:volume10lld:pubmed
pubmed-article:1398513pubmed:ownerNLMlld:pubmed
pubmed-article:1398513pubmed:authorsCompleteYlld:pubmed
pubmed-article:1398513pubmed:pagination171-9lld:pubmed
pubmed-article:1398513pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:meshHeadingpubmed-meshheading:1398513-...lld:pubmed
pubmed-article:1398513pubmed:articleTitle'Aggressive' low grade lymphocytic lymphomas can be identified by flow cytometric S-phase determinations.lld:pubmed
pubmed-article:1398513pubmed:affiliationDepartment of Oncology, University Hospital of Umeå, Sweden.lld:pubmed
pubmed-article:1398513pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1398513pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed